Trial Profile

Mabtornib Protocol. Vascular, Metabolic and Hormonal Effects of Angiogenesis Inhibitors and Epidermal Growth Factor Receptor Inhibitors

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
Indications Cancer metastases
Focus Adverse reactions
Acronyms Mabtornib

Most Recent Events

06 Oct 2015 Biomarkers information updated
31 Jan 2013 Planned End Date changed from 1 Apr 2011 to 1 Apr 2015 as reported by ClinicalTrials.gov.
29 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com